Sigrid Secures $5 Million to Enhance Non-Systemic Metabolic Health Solutions

Sigrid, a Swedish consumer health company known for its innovative approach to metabolic health, has recently announced a successful fundraising round, securing USD 5 million in funding. This new influx of capital brings the company's total raised to approximately USD 27 million. The participation from both existing and new international investors reflects the growing confidence in Sigrid’s clinically validated platform and the company's increasing commercial traction in the United States market.

In an era where metabolic health is gaining global attention, individuals, clinicians, and consumers are actively seeking practical and scientifically-supported solutions that can yield noticeable improvements in blood sugar levels and weight management. Sigrid's dietary supplement, known as Glucose Stabiliser, is witnessing rapid acceptance in direct-to-consumer channels as well as among U.S. healthcare providers. Over the last year alone, the product has experienced more than threefold revenue growth, highlighting not only its effectiveness but also a strong product-market fit and persistent consumer usage within a rapidly expanding sector.

According to Sana Alajmovic, Co-Founder and CEO of Sigrid, "We are observing a fundamental transformation in public attitudes towards metabolic health. Control of blood sugar levels and sustainable weight management have emerged as critical concerns for many, and there is growing demand for solutions that are clinically validated. Sigrid is uniquely positioned with one of the most robust non-systemic platform technologies in this category to meet that demand. The recent investment will enable us to speed up our U.S. expansion while also advancing new sectors powered by our SiPore® technology."

Advancements in Regulatory Approvals and Platform Expansion

Following the successful completion of its technical file for CE-mark approval in the EU, Sigrid is making headway towards the authorization of an innovative over-the-counter medical device designed to aid weight reduction and metabolic wellness for adults dealing with excess weight and elevated blood sugar levels. This initiative is part of a structured lifestyle management program aimed at transforming how individuals manage their health.

In addition to this, Sigrid is broadening the application of its SiPore® platform beyond just metabolic health, signaling exciting growth prospects in other fields such as oral care, veterinary health, and food technology. The company is currently in discussions with several prominent organizations in consumer health, nutrition, and pharmaceuticals regarding licensing and distribution partnerships, allowing global brands to leverage SiPore®-powered innovations and deliver them to millions of consumers worldwide.

About Sigrid

Sigrid stands at the forefront of the Swedish medtech and consumer health landscape, dedicated to revolutionizing metabolic health through scientifically-backed, non-systemic technologies. Backed by over 15 years of extensive research, Sigrid's patented SiPore® technology operates mechanically in the gut without entering the bloodstream, offering a safe and effective solution for managing everyday glucose levels and weight challenges. This innovative platform serves as the basis for future developments not only in metabolic health but also in oral health, veterinary care, and food technology. For more information, visit Sigrid's Official Website.